Breaking Down Barriers to Biosimilar Access
November 26, 2025
-
7 min
Two decades post the introduction of biosimilars in Europe, access, confidence, and sustainability continue to shape their integration into healthcare. With Biocon Biologics' approval of denosumab biosimilars, efforts focus on regulatory innovation and collaborative strategies to enhance availability across Europe. Initiatives in various countries, including educational programs and financial incentives, aim to support adoption among healthcare providers and improve patient outcomes. Biocon emphasizes its commitment to providing essential medicines in chronic areas such as oncology and diabetes, while navigating a competitive biosimilar market to ensure reliable supply and affordability.
1. Biosimilars have been in Europe for 20 years. 2. Biocon's denosumab biosimilars focus on access and affordability. 3. Various countries use policies to promote biosimilar adoption. 4. The EMA aims to streamline the biosimilar approval process. 5. Biocon's portfolio includes oncology and diabetes therapies. 6. Collaboration with healthcare systems is essential for biosimilar integration.
Listen Tab content
